SLC1A2-AS1

Across TCGA pan-cancer cohorts, SLC1A2-AS1 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of SLC1A2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where SLC1A2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC1A2-AS1 is over-expressed in tumor, although a few such as ESCA show the opposite, repressed pattern.

BRCA, PAAD, and ESCA are the cancer types where SLC1A2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC1A2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	II,III,IV	+0.070	.001	4	view →
PAAD	Male	All	+0.160	.015	2	view →
ESCA	All	All	−0.078	.007	2	view →
KICH	All	All	+0.063	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

SLC1A2-AS1–BRCA

Open the BRCA breakdown →